Contact us   |  

Treatment of AML in the elderly. Intensive or not ?

Treatment of AML in the elderly. Intensive or not ?

03/12/2020 17:00

Speakers: Gert Ossenkoppele

Target: Health professionals
Subnetworks: Myeloid malignancies
Disease Groups: Acute myeloid leukemia (AML)

Gert Ossenkoppele is appointed in 2003 as professor of Hematology at the VU University Medical Center in Amsterdam. He obtained his doctorate of medicine at that same University in 1977. He is board certified in Hematology and Internal medicine(1984). The title of his PhD thesis (1990) was: "Differentiation induction in AML". Gert Ossenkoppele has authored over 400 publications in peer-reviewed journals and is invited speaker at many national and international scientific meetings. His research interests is mainly translational and include the (stem cell) biology of AML, leukemic stem cell target discovery, immunotherapy and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML. He is PI of national and international clinical trials in myeloid malignancies. He is reviewer on a regular basis for many high impact hematological journals (Blood, Leukemia, Haematologica, Oncotarget, NEJM). He chairs the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is appointed as vice-chair of the HOVON Executive Board. He is a lead participant of the AML Work package of the European LeukemiaNet (ELN) as well as a board member of the ELN foundation. He leads the AML WP of HARMONY. He  rotated of as board member of the European Hematology Association and very recently appointed as chair of the EHA Educational Committee. He just rotated of as chair of the AML Scientific working group of EHA. He is chair of the Global and EU steering committee of the AMLGlobalPortal an educational portal for hematologists. He chairs the institutional DSMB of his University. He has now because of retirement an honorary position as hematologist at the Amsterdam University Medical center.